De-escalation of Imipenem/Cilastatin plus Vancomycin

De-escalation of Imipenem/Cilastatin plus Vancomycin Therapy for Critically Ill Patients with Hospital-Acquired Pneumonia: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0000065

Enrollment

120

Registered

2010-12-17

Start date

2004-11-08

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : De-escalation (DE) patients received imipenem/cilastatin (0.5 g every 6 hours) and vancomycin (15 mg/kg every 12 hours). If renal or hepatic functional impairment was present, the dosages were

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Included if all the following criteria were met; (i) hospitalized > 48 hours, (ii) aged over 18 years, and (iii) admitted to ICU to treat established HAP.

Exclusion criteria

Exclusion criteria: Excluded if any one of the following; (i) previous identification of the organisms of pneumonia, (ii) previous change of the antimicrobial regimen for HAP > 48 hours before ICU admission, (iii) pregnancy or lactation, or (iv) previous history of HAP within 1 month before the enrollment.

Design outcomes

Primary

Measure	Time frame
antimicrobial adequacy	—

Secondary

Measure	Time frame
mortality;duration of antimicrobial treatment;emergence of multidrug-resistant organisms;ICU stay	—

Countries

Korea, Republic of

Contacts

Public ContactJong Wook Kim

Asan Medical Center

Outcome results